See the DrugPatentWatch profile for lurbinectedin

Yes, there may be potential risks associated with the use of lurbinectedin. According to the drug's prescribing information, common adverse reactions include fatigue, nausea, vomiting, diarrhea, decreased appetite, constipation, and increased liver enzymes [1]. Additionally, more serious risks such as severe neutropenia, febrile neutropenia, and thrombocytopenia have been reported [1]. Furthermore, lurbinectedin may cause harm to a developing fetus and should not be used during pregnancy [1].

It is also important to note that lurbinectedin is a relatively new drug, and long-term safety data is still being collected. Therefore, it is possible that additional risks may be identified as more patients are treated with the drug.

Another potential risk associated with lurbinectedin is its cost. According to DrugPatentWatch.com, as of 2021, there are no generic versions of lurbinectedin available, and the drug is currently under patent protection [2]. This means that the drug's manufacturer, PharmaMar, can set the price of the drug. As of 2021, the cost of lurbinectedin is approximately $15,000 per month [3]. This high cost may be a barrier to access for some patients.

In summary, lurbinectedin has been associated with a number of potential risks, including common adverse reactions, serious hematologic toxicities, and potential harm to a developing fetus. Additionally, the drug's high cost may be a barrier to access for some patients. It is important for patients and healthcare providers to carefully consider these risks when deciding whether to use lurbinectedin.

Sources:

1. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214473s000lbl.pdf>
2. <https://www.drugpatentwatch.com/drugs/lurbinectedin>
3. <https://www.treato.com/Lurbinectedin/?a=s&q=Lurbinectedin>